http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#Head http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#provenance http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#pubinfo http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion http://purl.obolibrary.org/obo/DOID_1406 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_1406 http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00873 http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association http://www.w3.org/2000/01/rdf-schema#label loteprednol etabonate is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva cornea and anterior segment of the globe such as allergic conjunctivitis acne rosacea superficial punctate keratitis herpes zoster keratitis iritis cyclitis selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation loteprednol etabonate is less effective than prednisolone acetate 1 in two 28 day controlled clinical studies in acute anterior uveitis where 72 of patients treated with loteprednol etabonate experienced resolution of anterior chamber cells compared to 87 of patients treated with prednisolone acetate 1 the incidence of patients with clinically significant increases in iop 1 mmhg was 1 with loteprednol etabonate and 6 with prednisolone acetate 1 loteprednol etabonate should not be used in patients who require a more potent corticosteroid for this indication loteprednol etabonate is also indicated for the treatment of post operative inflammation following ocular surgery http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00873 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#provenance http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#pubinfo http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig http://purl.org/nanopub/x/hasSignature NA47n7lIaDTmZr3Sy3Iim1W0yz8c5goZgQ8WF9DnJu34LYUq53OYovD9JXwECWP262+Vjx7SaVhEYfKwHYRA06netMCso5ziD7tsFz725VSOy7JMtPXNclq4+KSy2/H4dGnjUAppvqQ2kFUjkaKt81FDR7n9My0z0CGzS8dXk9A= http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://purl.org/dc/terms/created 2021-06-12T15:45:39.687+02:00 http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAgoiNAigCeEDdxhR2jlxsbu2uzhCvYPh-wNKmrR8Htto https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs